Ryan D. Wuebbles, Ph.D.
Affiliations: | 2009 | University of Illinois, Urbana-Champaign, Urbana-Champaign, IL |
Google:
"Ryan Wuebbles"Parents
Sign in to add mentor| Andrew Belmont | grad student | 2009 | UIUC | |
| (Altered FRG1 levels during Xenopus laevis development leads to muscular and vascular phenotypes supporting a role for the misregulation of FRG1 in FSHD.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ba MA, Aiyuk A, Hernández K, et al. (2022) Transgenic overexpression of α7 integrin in smooth muscle attenuates allergen-induced airway inflammation in a murine model of asthma. Faseb Bioadvances. 4: 724-740 |
| Jones TI, Chew GL, Barraza-Flores P, et al. (2020) Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity. Skeletal Muscle. 10: 8 |
| Barraza-Flores P, Fontelonga TM, Wuebbles RD, et al. (2019) Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of Duchenne muscular dystrophy. Human Molecular Genetics |
| Fontelonga TM, Jordan B, Nunes AM, et al. (2019) Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of duchenne muscular dystrophy. Human Molecular Genetics |
| Wuebbles RD, Cruz V, Van Ry P, et al. (2019) Human Galectin-1 Improves Sarcolemma Stability and Muscle Vascularization in the mdx Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy. Methods & Clinical Development. 13: 145-153 |
| Sarathy A, Wuebbles RD, Fontelonga TM, et al. (2017) SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Nunes AM, Wuebbles RD, Sarathy A, et al. (2017) Impaired fetal muscle development and JAK-STAT activation mark disease onset and progression in a mouse model for merosin-deficient congenital muscular dystrophy. Human Molecular Genetics |
| Van Ry PM, Wuebbles RD, Key M, et al. (2015) Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 1285-97 |
| van Ry PM, Wuebbles RD, Key M, et al. (2015) Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy Molecular Therapy |
| Wuebbles RD, Sarathy A, Kornegay JN, et al. (2013) Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy. Disease Models & Mechanisms. 6: 1175-84 |